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Cell–cell communicationCholangiocarcinoma (CCA), a common primary malignant tumor of bile duct epithelia, is highly prevalent in
Asian countries and unresponsive to chemotherapeutic drugs. Thus, a newly recognized biological entity for
early diagnosis and treatment is highly needed. Exosomes are small membrane bound vesicles found in body
ﬂuids and released by most cell types including cancer cells. The vesicles contain speciﬁc subset of proteins
and nucleic acids corresponding to cell types and play essential roles in pathophysiological processes. The present
study aimed to assess the protein proﬁles of CCA-derived exosomes and their potential roles. We have isolated
exosomes from CCA cells namely KKU-M213 and KKU-100 derived from Thai patients and their roleswere inves-
tigated by incubation with normal human cholangiocyte (H69) cells. Exosomes were internalized into H69 cells
and had no effects on viability or proliferation of the host cells. Interestingly, the exosomes from KKU-M213 cells
only induced migration and invasion of H69 cells. Proteomic analysis of the exosomes from KKU-M213 cells
disclosed multiple cancer related proteins that are not present in H69 exosomes. Consistent with the protein
proﬁle, treatment with KKU-M213 exosomes induced β-catenin and reduced E-cadherin expressions in H69
cells. Collectively, our results suggest that a direct cell-to-cell transfer of oncogenic proteins via exosomal path-
way may be a novel mechanism for CCA progression and metastasis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cholangiocarcinoma (CCA), a severe neoplasm of biliary tract
epithelia [1], is the secondmost commonprimary hepatic tumor globally
[2]. CCA is often enigmatic, characterized by poor prognosis, and unre-
sponsive to chemotherapeutic agents [3]. This type of cancer represents
10–25% of primary liver cancers worldwide and is highly prevalent in
Asian countries including Thailand [4]. It responds poorly to the presently
available therapies [5] and surgical resection is the only mean to extend
lifespan for no more than 5 years [6]. It is, therefore, considered to be
an incurable and rapidly lethal malignancy. In view of the lack of a valid
early stage detection method and potential curative treatment, an effec-
tive early detection and/or an alternative therapeutic strategy with high
sensitivity to speciﬁc targets is urgently needed.y, Faculty of Science, Mahidol
iland.
gdua).Exosomes are small (40–100 nm in diameter) membrane bound
vesicles that are initially formed within the endosomal compartment
and secreted upon fusion of the limiting membrane of multi-vesicular
bodies (MVBs) with plasmamembrane [7]. These homogeneous vesicles
are released by most of cell types including cancer cells and are consid-
ered as messengers of intercellular communications [8]. Biochemical
and proteomic analysis of exosomes reveal that, besides a common set
of membrane and cytosolic molecules, these vesicles contain cell and
cell state speciﬁc cargos of proteins, mRNAs, and miRNAs that character-
ize their functional activities [9]. Of particular interest, tumor cells exhibit
enhanced production of exosomes. The exact function and the need of
such high amount of exosomes in malignant cells are not clearly under-
stood. Recent investigations suggest the roles in cell-to-cell communica-
tion, tumor–stroma interaction, antigen presentation and establishment
of tumor microenvironments that potentially uphold cancer progression
at different steps [10]. Although exosomes from a variety of cell types
have been isolated and characterized and their functions have been pre-
viously reported, the presence and the role of exosomes in CCA carcino-
genesis are presently not known. We hypothesized that CCA cells may
1990 S. Dutta et al. / Biochimica et Biophysica Acta 1852 (2015) 1989–1999manufacture exosomes that reinforce CCA development. The present
piece of work investigated whether CCA cells produce exosomes and
what are their potential roles on malignant phenotypes. We found that
KKU-M213 cells, an aggressive human CCA cell line, released exosomes
in culture media with basic characteristics similar to those isolated
from other sources [11]. A comparative proteomics approach between
KKU-M213 and human cholangiocyte (H69) exosomes disclosed vast
differences in their active protein contents. Furthermore, exosomes
fromKKU-M213 cells increasedmotility and altered cell adhesion relat-
ed protein expressions in recipient H69 cells. Our results indicate that
exosomes may play a role on CCA pathogenesis and identiﬁcation of
their cargo proteins may serve as a biomarker for early detection and
thus might enlighten new treatment strategies.
2. Materials and methods
2.1. Reagents and antibodies
Ham's F12 nutrient mixture, DMEM, DMEM/F-12 media and
antibiotic–antimycotic were purchased from Invitrogen (CA, USA).
Fetal bovine serum (FBS), protease and phosphatase inhibitor, adenine,
insulin, epinephrine, 3,3′,5 Triiodothyronine, apo-transferrin, epider-
mal growth factor and hydrocortisone were obtained from Sigma-
Aldrich Co. (MO, USA). RIPA cell lysis buffer and SuperSignal West
Pico Chemiluminescent Substrate were purchased from Thermo Scien-
tiﬁc (Cramlington, UK). Anti-ﬂotillin-1 and anti-E-cadherin primary an-
tibodies were purchased from BD Biosciences (CA, USA). Anti-GSK3β
and anti-phospho-GSK3β (Ser-9) were obtained from Cell Signal Tech-
nologies (MA, USA). Anti-β-catenin and anti-CD81 (B-11) antibodies
were from Santa Cruz Biotechnology, Inc. (TX, USA). Anti-
TSG101[4A10] and anti-CD63 were from abcam (Cambridge, UK).
Anti-β-actin was form Sigma-Aldrich Co. (MO, USA). Trans-well cham-
bers were obtained from Corning Life Sciences (MA, USA). All other re-
agents were of the highest analytical grades available and unless
otherwise stated were purchased from Sigma-Aldrich (MO, USA).
2.2. Cell culture
KKU-100 and KKU-M213, the CCA cell lines established from primary
tumors of Opisthorchiasis-associated Thai CCA patients [12], were kindly
provided by Dr. Banchob Sripa. KKU-100 is poorly differentiated adeno-
carcinoma cell linewith compact polygonal to spindle shape [12]whereas
KKU-M213 is well-differentiated adenocarcinoma cell line [13,14]. These
cells were cultured in Ham's F12 nutrient media, supplementedwith 10%
heat inactivated FBS and 1% antibiotic–antimycotic, at 37 °C in a humidi-
ﬁed 5% CO2 incubator. A human cholangiocyte cell line (H69) immortal-
ized with the simian virus 40 (SV40) large T antigen was obtained from
Dr. Gregory J. Gores, Mayo Clinic College of Medicine and cultured in
DMEM/Ham-F12 media containing 10% FBS. Although immortal, this
cell line is non-malignant; in vitro, it does not display anchorage indepen-
dent growth and, in vivo, it does not produce tumors in nude mice [15].
2.3. Exosome isolation
CCA or H69 cells were plated in 75 cm2 culture ﬂasks. Cells were
cultured in conditioned medium depleted of contaminating vesicles
and protein aggregates by overnight centrifugation at 110,000 ×g.
Culture supernatants were collected 48 h after changing the medium
and exosomes were puriﬁed by differential centrifugation as described
previously [16]. Brieﬂy, culture supernatant was collected and ﬁrst
centrifuged 300 ×g at 4 °C for 10 min to remove lifted cells followed by
centrifugation at 1,200 ×g for 10 min and 10,000 ×g at 4 °C for 30 min
to remove cell debris. The resultant supernatant was subjected to ﬁltra-
tion on 0.22 μm pore ﬁlters, followed by ultracentrifugation (Beckman
Coulter Inc.; CA, USA) at 110,000 ×g for 70 min. The resulting pellets
were re-suspended in chilled PBS, pooled, and again ultra-centrifugedat 110,000 ×g for 70 min at 4 °C. The ﬁnal pellet of exosomes was re-
suspended in 50–100 μl PBS, aliquoted and stored at−80 °C until use.
2.4. Electron microscopy
For electron microscopic (EM) observation of exosomes, pellets ob-
tained after centrifugation at 110,000×gwereﬁxed in 4%paraformalde-
hyde (PFA) (1:1 ratio) for 10min and loaded on Formvar/carbon-coated
EM grids by ﬂoating the grid over small drops of PBS containing ﬁxed
exosomes. The exosomes were then post ﬁxed in 1% glutaraldehyde
for 5 min and contrasted successively in freshly prepared 2% uranyl
acetate, pH 7, and 2% methylcellulose/0.4% uranyl acetate, pH 4. Obser-
vations were made with a FEI Technai G2 electron microscope (The
Netherlands) equipped with a thermionic tungsten ﬁlament and operat-
ed at an acceleration voltage of 120 kV. Images were taken with a cooled
slow-scan CCD camera at a magniﬁcation of 50,000×.
2.5. Migration and invasion assay
Cell migration and invasion assays were performed using trans-well
chambers with polycarbonate inserts containing 8 μm pores, as de-
scribed elsewhere [17]. Brieﬂy, H69 cells were detached from culture
plates by gentle pipetting. Cells (1 × 105 cells) were mixed with PBS
or 200 μg/ml exosomes from either H69 cells or CCA cells, placed inside
the upper chamber, and maintained in serum- and growth factor-freed
medium for 48 h. For an invasion assay, a thin layer of matrigel was
layered on top of the insert in the upper chambers. Cells, incubated at
37 °C in a humidiﬁed 5% CO2 incubator, were allowed to migrate or in-
vade for 48 h to the lower chamber containing 750 μl culture medium
supplemented with 20% exosome-freed FBS as chemo-attractant. After
incubation, non-migrated and non-invaded cells in the upper chamber
were completely removed using cotton swabs. Cells that had migrated
or invaded across the porous membrane were ﬁxed in 25% methanol
for 30 min, stained with DAPI (1 μg/ml) for 5 min in darkness or 0.5%
crystal violet and washed 3 times. The membranes were carefully re-
moved and mounted on slides. The nuclei of migrated and invaded
cells were observed under a confocal ﬂuorescence microscope and
photographed. Cells were automatically counted using image J soft-
ware. The background was subtracted using rolling ball feature, jointed
cellswere separated bypixelmapping andparameter of the softwarewas
set to exclude particles of smaller or bigger than the average nuclear size
to minimize erroneous counting.
2.6. Cell viability and cell proliferation assay
Cell viability was measured by MTT assay. H69 cells were plated
in 96-well plates for 24 h. The supernatants were withdrawn from
sub-conﬂuent cultures, the cells were washed with serum-freed me-
dium and incubated with PBS or 200 μg/ml of exosomes from either
H69 or CCA cells, in serum- and growth factor-freed medium for 12,
24 or 48 h. Culture supernatants were then carefully removed andMTT
(0.5 mg/ml) solutions were added and incubated at 37 °C, 5% CO2 incu-
bator for 4 h. Then, MTT solutions were removed and 100 μl DMSO was
added to dissolve the formazan crystals before measurement at an ab-
sorbance of 590nmbyMultiskanmicro plate reader (Thermo Scientiﬁc;
Cramlington, UK). The result was calculated as % of cell viability. Cell
proliferation upon exosomes treatment was further analyzed by stain-
ing Ki67 protein in growing cells. H69 cells were cultured on cover
slips in 24-well culture plates. After 24 h, supernatantswerewithdrawn
from sub-conﬂuent cultures, the cells were washed with serum-freed
medium and incubated with PBS or 200 μg/ml of exosomes from either
H69 or CCA cells, in serum- and growth factor-freedmedium. After cul-
ture, supernatants were carefully removed, cells were washed twice in
PBS and ﬁxed in 4% PFA. Cells were then blocked in 10% BSA for 1 h,
washed in PBS and incubated with cocktail antibody solution in 1%
BSA containing anti-ki67 and anti-actin antibodies for 2 h at room
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ﬂuorescent tagged secondary antibodies for another 1 h at room
temperature in darkness. Cells were then washed and nuclei were
counter stained with DAPI (0.5 mg/ml) for 5 min, mounted on glass
slides and visualized under a confocal microscope (Fluoview fv10i,
Olympus).
2.7. SDS-PAGE and nano LC/MS/MS
Exosome samples (30 μg) from H69 and KKU-M213 cells were
re-suspended in NuPAGE SDS sample buffer and separated under
reducing conditions on NuPAGE 3–8% gradient precast tris-acetateTable 1
Protein identiﬁcation from H69 and KKU-M213-derived exosomes.
No Accession no. Protein
1 CLH1_HUMAN Clathrin heavy chain 1
2 FINC_HUMAN Fibronectin
3 HSP7C_HUMAN Heat shock cognate 71 kDa protein
4 PDC6I_HUMAN Programmed cell death 6-interacting pro
5 UBIQ_HUMAN Ubiquitin
6 EF1A1_HUMAN Elongation factor 1-alpha 1
7 HS90B_HUMAN Heat shock protein HSP 90-beta
8 ACTB_HUMAN Actin, cytoplasmic 1
9 TERA_HUMAN Transitional endoplasmic reticulum ATPa
10 HSP76_HUMAN Heat shock 70 kDa protein 6
11 ANXA2_HUMAN Annexin A2
12 ACTBL_HUMAN Beta-actin-like protein 2
13 ALBU_HUMAN Serum albumin
14 TS101_HUMAN Tumor susceptibility gene 101 protein
15 LRRK2_HUMAN Leucine-rich repeat serine/threonine-pro
16 ATD3B_HUMAN ATPase family AAA domain-containing p
17 RRBP1_HUMAN Ribosome-binding protein 1
18 LG3BP_HUMAN Galectin-3-binding protein
19 FPRP_HUMAN Prostaglandin F2 receptor negative regul
20 4F2_HUMAN 4F2 cell-surface antigen heavy chain
21 MVP_HUMAN Major vault protein
22 ITB1_HUMAN Integrin beta-1
23 AT1A1_HUMAN Sodium/potassium-transporting ATPase
24 TSP1_HUMAN Thrombospondin-1
25 K1199_HUMAN Protein KIAA1199
26 TACD2_HUMAN Tumor-associated calcium signal transdu
27 EF2_HUMAN Elongation factor 2
28 1A01_HUMAN HLA class I histocompatibility antigen, A
29 G3P_HUMAN Glyceraldehyde-3-phosphate dehydroge
30 ITB4_HUMAN Integrin beta-4
31 LAMC1_HUMAN Laminin subunit gamma-1
32 1B55_HUMAN HLA class I histocompatibility antigen, B-
33 TPP2_HUMAN Tripeptidyl-peptidase 2
34 TINAL_HUMAN Tubulointerstitial nephritis antigen-like
35 HSP71_HUMAN Heat shock 70 kDa protein 1A/1B
36 ANXA1_HUMAN Annexin A1
37 HS90A_HUMAN Heat shock protein HSP 90-alpha
38 BASI_HUMAN Basigin
39 UBA1_HUMAN Ubiquitin-like modiﬁer-activating enzym
40 IMB1_HUMAN Importin subunit beta-1
41 IGSF8_HUMAN Immunoglobulin superfamily member 8
42 ITA3_HUMAN Integrin alpha-3
43 ITA2_HUMAN Integrin alpha-2
44 TBB2C_HUMAN Tubulin beta-2C chain
45 APOB_HUMAN Apolipoprotein B-100
46 VTNC_HUMAN Vitronectin
47 MFGM_HUMAN Lactadherin
48 ITA6_HUMAN Integrin alpha-6
49 EPCAM_HUMAN Epithelial cell adhesion molecule
50 KPYM_HUMAN Pyruvate kinase isozymes M1/M2
51 TBA1B_HUMAN Tubulin alpha-1B chain
52 PLAK_HUMAN Junction plakoglobin
53 ARRD1_HUMAN Arrestin domain-containing protein 1
54 AAAT_HUMAN Neutral amino acid transporter B(0)
55 PGBM_HUMAN Basement membrane-speciﬁc heparan su
56 PB1_HUMAN Protein polybromo-1
57 CENPE_HUMAN Centromere-associated protein E
NI: No identiﬁcationand NQ: no quantiﬁcation by emPAI.SDS–polyacrylamide gel (Life Technologies; NY, USA). Gels were
stained with Coomassie brilliant blue g-250 gel staining solution
(Bio-Rad; CA, USA), and de-stained in ultrapure LC/MS grade water
(Fisher Scientiﬁc; Loughborough, UK). Each gel lane was trimmed
in pieces and de-stained in 50% acetonitrile (in 25 mM NH4HCO3)
until colorless. Freshly prepared 10 mM dithiothreitol (in 25 mM
NH4HCO3) was added to reduce the proteins for 15 min at 60 °C.
The gel pieces were cooled down to room temperature and freshly
prepared 55 mM iodoacetamide (in 25 mM NH4HCO3) were added
to alkylate the proteins for 30 min at room temperature in the
dark. Thereafter, solutions were removed and acetonitrile was
added to dehydrate gel pieces. The gel pieces were allowed to dryemPAI
H69 KKU-M213
0.49 ± 0.03 0.41 ± 0.04
0.2 ± 0.05 0.1 ± 0.03
0.75 ± 0.05 0.17 ± 0.1
tein 0.52 ± 0.17 0.7 ± 0.11
6.06 ± 1.24 3.77 ± 1.52
0.43 ± 0.01 NI
0.19 ± 0.28 NI
0.29 ± 0.00 0.29 ± 0.00
se 0.18 ± 0.00 0.18 ± 0.00
0.17 ± 0.03 NI
0.32 ± 0.00 0.32 ± 0.00
0.19 ± 0.00 0.19 ± 0.00
0.17 ± 0.00 0.3 ± 0.00
0.28 ± 0.07 NI
tein kinase 2 NQ NI
rotein 3B NQ NI
NQ NI
NI 1.56 ± 0.23
ator NI 0.68 ± 0.07
NI 0.89 ± 0.04
NI 0.44 ± 0.06
NI 0.39 ± 0.1
subunit alpha-1 NI 0.21 ± 0.13
NI 0.18 ± 0.02
NI 0.15 ± 0.04
cer 2 NI 0.49 ± 0.09
NI 0.16 ± 0.01
-1 alpha chain NI 0.55 ± 0.07
nase NI 0.35 ± 0.09
NI 0.07 ± 0.00
NI 0.06 ± 0.00
55 alpha chain NI 0.3 ± 0.07
NI 0.14 ± 0.04
NI 0.23 ± 0.01
NI 0.11 ± 0.00
NI 0.2 ± 0.09
NI 0.14 ± 0.06
NI 0.29 ± 0.08
e 1 NI 0.1 ± 0.00
NI 0.08 ± 0.00
NI 0.18 ± 0.00
NI 0.1 ± 0.00
NI 0.09 ± 0.02
NI 0.16 ± 0.11
NI 0.01 ± 0.00
NI 0.14 ± 0.06
NI 0.09 ± 0.02
NI 0.06 ± 0.00
NI 0.23 ± 0.1
NI 0.13 ± 0.07
NI 0.15 ± 0.08
NI 0.09 ± 0.00
NI 0.17 ± 0.00
NI 0.14±
lfate proteoglycan core protein NI 0.01±
NI NQ
NI NQ
1992 S. Dutta et al. / Biochimica et Biophysica Acta 1852 (2015) 1989–1999completely in a fume hood. Trypsin solution (0.01mg/ml) was added
to digest the gel pieces and incubated at 37 °C overnight. The pep-
tides were extracted by adding acetonitrile (10 mg/ml in 50% HPLC
grade acetonitrile, 0.1% TFA) and subsequently concentrated using
a concentrator. The samples were stored at −20 °C prior to mass
spectrometric analysis. Each tryptic digested fractions were re-
suspended in 0.1% formic acid containing 2% acetonitrile and analyzed
by MicroToF Q II mass spectrometer (Bruker; Bremen, Germany). The
front end of the mass spectrometer was coupled with an Ultimate 3000
nano-LC system (Dionex; Surrey, UK). The separation was done at
a ﬂow rate of 300 nl/min. Mobile phase A (2% (v/v) acetonitrile,
0.1% (v/v) formic acid in HPLC grade water) and mobile phase B
(0.1% (v/v) formic acid in HPLC grade acetonitrile) were used to establish
45 min gradient. The gradient started with 10 min 2–10% B, followed by
33 min 10–40% B, ramped rapidly (1 min) 40–95% B and maintained at
95% B for 1 min. The eluent was sprayed and ionized in the nano-
electrospray source of the mass spectrometer. Data were acquired usingFig. 1. Characterization of exosomes puriﬁed from CCA cell lines. Transmission electronmicrosc
(D)Western blot analysis of exosomemarker proteins. Total cell lysates and isolated exosome fr
cell lines were separated by 10% SDS-PAGE followed byWestern blotting with speciﬁc antibodHystar software. The MS and MS/MS spectra were acquired in mass
range of m/z 400–2000 m/z 50–1500, respectively.
2.8. Analysis of LC/MS/MS data
The mass spectrometric data was smoothed, centroided and con-
verted into a mascot generic ﬁle (.mgf) using data analysis software
version 4.0. Mascot v.2.3.0 (Matrix Science, London, UK) was used to
search data against Swissprot_57.15 (total sequences is 515203)
human protein database using trypsin with one possible missed
cleavage allowed at 1. The mass tolerances for precursor and fragment
ions were set to 1.2 Da and 0.6 Da, respectively. The peptide charge
was selected as 2+, 3+ and 4+. Oxidations of methionine and carba-
midomethylation of cysteine were set as variable modiﬁcations. To re-
duce false positive identiﬁcation, only peptides scored above 20 were
reported in this study and each identiﬁed protein contained at least 2
peptides. Due to the same amount of proteins loaded into SDS-PAGE,opic images of exosomes isolated from (A) H69, (B) KKU-100, and (C) KKU-M213 cell lines.
actions (50 μg for CD63, 25 μg for ﬂotillin-1, 1 μg for TSG101 andCD81) from three different
ies. Bars = 50 nm.
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exponentially modiﬁed protein abundance index (emPAI) provided by
the Mascot. The emPAI value is based on an equation shown below:
emPAI ¼ 10
Nobserved
Nobservable−1
where Nobserved is the number of experimentally observed peptides and
Nobservable is the calculated number of observable peptides for each pro-
tein [18]. The success of this label freed quantitative approach has been
shown in many studies. Indeed, secretomes of Aspergillus fumigatus
were proﬁled at different temperatures [19]. Moreover, the mannose-
binding proteins (MBPs) from the normal donor and hepatocellular
carcinoma (HCC) patient sera were also quantiﬁed by emPAI [20]. All
emPAI values in Table 1 are means of three MS analysis. Protein class
and pathway categorization were carried out using Panther classiﬁca-
tion system available at http://www.pantherdb.org/. The functional an-
notation of identiﬁed proteins wasmainly retrieved from the Swissprot
database (http://www.uniprot.org/).
2.9. Western blot analysis
H69 cells were cultured on 6-well culture plates. After treatment
with exosomes in serum- and growth factor-freed medium for the
desired period, cells were washed thrice with chilled PBS. Cells were
then harvested, lysed with radio-immuno-precipitation assay (RIPA)Fig. 2. Effects of H69- and CCA-derived exosomes on H69 cell migration and invasion. (A) KKU-
chamber of trans-well in exosome-depleted and growth factor-freedmedium. Cells were then i
cell lines for 48 h. Non-migrated cellswere removed by cotton swab.Migrated cells in the lower
microscope. (B) KKU-M213-derived exosomes induced H69 cell invasion. The invasion assay w
the insert in the upper chamber of trans-well. Non-invaded cells were removed by cotton swab
under a confocal ﬂuorescencemicroscope. Bar graphs are quantitative analyses of the number o
change. *p b 0.01; and **p b 0.001 compared to PBS control (ANOVA).cell lysis buffer (50 mM Tris–HCL pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 1mMNaF, 1mMNa3VO4, 1mMPMSF) containing pro-
tease and phosphatase inhibitors. Lysates were cleared by centrifuga-
tion at 14,000 ×g for 20 min at 4 °C. The supernatant fractions were
used for Western blotting. The protein concentrations were measured
using BCA (Bicinchoninic acid) protein assay kit (Thermo Fisher; MA,
USA). Equal amount of protein extracts from different treatment sets
were mixed with Laemmli sample buffer and heated at 95 °C for
5 min. The proteins were resolved by 10% SDS-PAGE and transferred
onto PVDF membrane at a constant voltage of 100 V at 4 °C for 2 h.
Membranes were blocked with 5% non-fat dry milk for 1 h at room
temperature and probed with indicated antibodies overnight at 4 °C.
Membranes were then washed thrice and incubated with HRP conju-
gated anti-mouse or anti-rabbit secondary antibody for 1 h at room
temperature and signals were detected using enhanced SuperSignal
West Pico Chemiluminescent (Thermo Scientiﬁc; MA, USA).
2.10. Confocal ﬂuorescence microscopy
H69 cells were plated on cover slips in 12-well plates for 24 h. Sub-
conﬂuent cell mono-layers were washedwith PBS and treated with PBS
or exosomes from either H69 or CCA cells in serum- and growth factor-
freed, and exosome-depletedmedium for the indicated time. Cells were
then washed thrice with cold PBS, ﬁxed with 4% PFA and completely
washed with PBS-Tween 20 (0.02% v/v). After blocking with 1% (w/v)
BSA at room temperature for 1 h, cells were treated with anti-mouseM213-derived exosomes induced H69 cell migration. H69 cells were cultured in the upper
ncubated with PBS or 200 μg/ml of exosomes isolated fromH69, KKU-100, and KKU-M213
chamber of trans-well were stainedwith DAPI and observed under a confocal ﬂuorescence
as performed as in themigration assay except a thin layer of matrigel was placed on top of
and invaded cells in the lower chamber of trans-well were stainedwith DAPI and observed
fmigrated and invaded cells. Data representmeans± S.E.M. (n= 5) and presented as fold
 12            24                 48
     Time (h)
125
100
75
50
25
0
PBS
H69
KKU-100
KKU-M213
KKU-M213
100
75
50
25
0
Ki67-
Ki67+
Fig. 3. Effects of exosomes on H69 cell viability and proliferation. (A) Exosomes isolated
fromCCA cell lines havenoeffect on cell viability. H69 cellswere cultured in 96-well plates
in complete medium. Cells were washed twice with PBS prior to incubation with PBS or
200 μg/ml of exosomes isolated from H69, KKU-100, and KKU-M213 cell lines in
exosome-depleted and growth factor-freedmedium for 12, 24, and 48 h. After incubation,
MTTdyewas added and incubated for 4h.DMSOwas added todissolve the formazan crystals
and colorimetric measurement was made at OD 590 nm. Data are means ± S.E.M. (n = 3)
and presented as % of control (PBS). (B) Effect of exosomes on Ki-67 protein expression in
H69 cells. H69 cells were routinely cultured on cover slips in 24-well plates for 24 h, washed
twice in PBS and incubated with either PBS or 200 μg/ml exosomes isolated from H69,
KKU-100, and KKU-M213 in exosome-depleted and growth factor-freed medium for
48 h. Cells were ﬁxed by 4% PFA and stained with anti-Ki-67 antibody. Cell nuclei were
stained with DAPI and visualized under a confocal microscope. (C) Bar graphs represent
percentages of Ki-67 positive cells among total number of cells in randomly observed
ﬁelds (n = 3).
1994 S. Dutta et al. / Biochimica et Biophysica Acta 1852 (2015) 1989–1999E-cadherin and anti-rabbit β-catenin antibodies cocktail overnight at
4 °C. Cells were washed with PBS three times for 5 min, and treated
with goat anti-mouse IgG (H + L) Alexa 488 and anti-rabbit IgG Alexa
568 (Invitrogen; CA, USA) in the blocking buffer at room temperature
for 1 h. The cells were subsequently washed with excess volumes of
PBS four times and stained with DAPI. Finally, each slide was mounted
and examined by a confocal ﬂuorescence microscopy (Fluoview fv10i,
Olympus). Representative images were chosen and digitally recorded
at the same sensitivity and magniﬁcation.
2.11. Statistical analysis
The statistically signiﬁcant differences among groups were compared
using one-way analysis of variance (ANOVA) followed by Tukey–Kramer
post hoc. Data were analyzed by using the statistical software package,
GraphPad Prism version 5.0.
3. Results
3.1. Characterization of exosomes released from CCA and human
cholangiocyte cells
To investigate the potential role of CCA cells derived exosomes in
tumor progression, the exosomes isolated from normal human
cholangiocyte cells (H69) and two human CCA cell lines (KKU-M213
and KKU-100) were ﬁrst analyzed by electron microscopy. As shown
in Fig. 1A–C, electron microscopy of negatively stained exosome prepa-
ration showed a characteristic saucer-like structure with a diameter
ranged from40 to 100 nmand crescent shapedmembrane invagination
that is limited by a lipid bilayer. SDS gel followed byWestern blotting of
whole cell lysates and exosome fractions revealed the well-known
multi-vesicular body markers ﬂotillin-1, TSG101, tetraspanin CD81 and
CD63 proteins, which were abundant in the exosomes of both H69 and
CCA cells (Fig. 1D). In addition, we have determined the viability of
H69, KKU-100 and KKU-M213 cell lines at the time of culture mediums
were collected for exosome isolation by trypan blue staining assay. We
found that more than 97% of cells were viable, indicating that exosomes
are released from viable CCA and cholangiocytes cells (data not shown).
The results suggest that, in CCA patients, these micro-vesicles are syn-
thesized in cholangiocarcinoma cells and may be secreted into the
circulation.
3.2. KKU-M213 exosomes promote H69 cell migration and invasion
Increases in cell migration, invasion, and proliferation are hallmarks
of cancer progression. The effects of CCA cells derived exosomes on H69
cell migration, invasion, and proliferation were, therefore, examined.
We cultured H69 cells on top of trans-well for cell migration assay. For
invasion assay a thin layer of matrigel was layered on top of trans-
well chambers. As shown in Fig. 2, exosomes derived from KKU-100
cells did not induce H69 cell migration (Fig. 2A) or invasion (Fig. 2B)
compared to PBS treated set. In contrast, exosomes isolated from
KKU-M213 cells not only increased the migration (Fig. 2A) but also
markedly increased the invasion of H69 cells (Fig. 2B). Of note,
exosomes from H69 cells failed to alter both H69 cell migration and in-
vasion. This was not due to the effect of differential exosome uptake by
H69 cells. Indeed, the exosomes isolated from all cell lines were able to
either be internalized or attached onto normal human cholangiocytes
(data not shown). Increases in cell migration and invasion may occur
as a result of an increase in cell proliferation.We next examinedwheth-
er adding exosomes puriﬁed from CCA cell lines to normal
cholangiocyte cells in culture would promote cell proliferation. As
shown in Fig. 3A, H69 cell proliferation was not affected upon exosome
treatments up to 48 h as depicted by MTT assay. The effect of different
set of exosomes on H69 cell proliferation was further conﬁrmed by
Ki67 staining, a marker protein for cell proliferation. Consistent with
1995S. Dutta et al. / Biochimica et Biophysica Acta 1852 (2015) 1989–1999theMTT data, the expression pattern of Ki67 protein was almost similar
in all conditions upon treatment with exosomes isolated from CCA cells
(Fig. 3B and 3C), suggesting that CCA-derived exosomes do not enhance
or suppress normal cell proliferation.
3.3. Proteomic analysis of exosomes derived from human cholangiocyte and
CCA cells
Exosomes isolated from KKU-M213 cells, but not from other set of
cells tested, promote H69 cell migration and invasion, suggesting the
different sets of proteins are carried by exosomes in normal and CCA
cell lines. We further investigated the protein composition in exosomes
isolated from KKU-M213 and H69 cells by proteomic approaches. First,
we separated the total exosomal proteins (30 μg) from KKU-M213 and
H69 cells by 3-8% gradient SDS-PAGE and stained with Coomassie
blue. The protein bands were distinctly different between two sets of
exosomes (data not shown). To identify the protein proﬁle of CCA and
H69 exosomes, individual slice of gels were subjected to in-gel trypsin
digestion followed by mass spectrometry. The data analysis using
Mascot database has identiﬁed proteins and their score for both H69
and KKU-M213 derived exosomes (Tables 1, S1 and S2). As shown in
Table 1, a number of proteins were exclusively found in the exosomes
puriﬁed from normal human cholangiocyte cells, not in KKU-M213
cells. Among the identiﬁed proteins, 10 proteins were found to be
expressed in both exosome samples. Interestingly, the exosomes isolated
from KKU-M213 cells accommodated 38 distinct proteins, compared to
those of H69 cells, including cancer related proteins such as galectin-3-
binding protein, prostaglandin F2 receptor negative regulator, 4F2heavyFig. 4. Proteomic analysis of puriﬁed exosomes from H69 and KKU-M213 cell lines. Classiﬁcatio
their protein classes using PANTHER Classiﬁcation System.chain, integrin-β1,major vault protein and integrinβ1 (Table 1). Our pro-
teomic results suggest that CCAmay promote cell invasion andmigration
via oncogenic molecules carried by exosomes.
Proteomics of shed vesicles, like exosomes, substantially contribute
to the understanding of biological functions of exosomes. Ontology
enrichment is the most ubiquitous type of functional analysis, which
evaluates relative representation of biological functions, or ontology
terms, such as pathways and cell processes, for the proteomic proﬁle
of interest. In our study, the Gene Ontology (GO) analysis by open
source panther database was employed for prediction of any speciﬁc
proteins or pathways that may affect H69 cells motility upon treatment
with KKU-M213 exosomes. As shown in Fig. 4A and B, different classes
of proteins with a variety of functions were identiﬁed in two different
sets of exosomes puriﬁed from cholangiocyte and CCA cell lines.
H69 exosomes contain higher chaperone and cytoskeletal proteins
(Fig. 4A). While, cell adhesion molecules, extracellular matrix protein,
oxidoreductase, receptor, transporter and protease were identiﬁed
only in KKU-M213 exosomes (Fig. 4B), indicating that CCA derived
exosomes are packedwith enormous functional ability and/or potential
to manipulate recipient cells in a wider aspect and that different to
those of normal cholangiocyte cells. Interestingly, pathway classiﬁca-
tion revealed that only the exosomal proteins from KKU-M213 cells
are related to metabolism and cancer-related signaling pathway such
as glycolysis, pyruvate metabolism, gonadotropin releasing hormone
receptor pathway, ubiquitin proteasome pathway and p53 pathway
(Fig. 5A and B). The number of proteins related to integrin signaling
pathway which plays an important role in cancer progression was in-
creased in exosomal proteins from KKU-M213 cells compared ton of proteins identiﬁed from H69 (A) and KKU-M213 (B) derived exosomes according to
Fig. 5. Proteomic analysis of puriﬁed exosomes from H69 and KKU-M213 cell lines. Classiﬁcation of proteins identiﬁed from H69 (A) and KKU-M213 (B) derived exosomes according to
their related pathways using PANTHER Classiﬁcation System.
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apoptosis pathway and other normal cellular activity was reduced.
Taken together, the results show that proteins identiﬁed in H69
exosomes are mostly meant for maintenance of normal cellular activity
compared to exosomes from KKU-M213 cells that are packed with set
of proteins having signiﬁcant potential to vast range of normal biologi-
cal functions and disease development such as cancer.
3.4. CCA exosomes alters E-cadherin and β-catenin expression in H69 cells
Since treatment with KKU-M213 exosomes increased invasion and
migration of H69 cells, we then assessed the cancer and cell motility re-
lated proteins, β-catenin and E-cadherin, by ﬂuorescence microscopy.
As shown in Fig. 6A, KKU-M213 exosomes increased β-catenin and
reduced E-cadherin expression in H69 cells whereas the expression
patterns remain unchanged after treatments with H69 or KKU-100
exosomes. Western blot analysis also conﬁrmed the increase (1.7
folds) in expression of β-catenin (Fig. 6B and C). However, the phos-
phorylation of GSK-3β, a well-known β-catenin regulator, was not
affected, suggesting that the increase in β-catenin expression in H69
cells was GSK-3β-independent. Collectively, these results indicate that
exosomes from CCA cells carry cancer-speciﬁc proteins thatmaymodu-
late normal cells toward tumor characteristics.
4. Discussion
Exosomes play a critical role in various pathological conditions [21].
Their biogenesis, intra-vesicular content, and transfer to recipient cellsare of enormous biological interest. Having a unique molecular cargo,
exosomes can reprogram the recipient cells. A number of recent studies
have demonstrated that tumor derived exosomes can modulate func-
tional geometry of recipient cells. It may help establish oncogenic
niche systematically via delivery of proteins, mRNAs or miRNAs,
which, in turn, promote cancer cell progression and metastasis [22].
Despite the potential importance of exosomes in the context of cancer
progression, the presence of exosomes in human CCA cell line and
their possible role in CCA pathogenesis have not yet been reported.
Herein we demonstrated for the ﬁrst time that two CCA cell lines de-
rived from Thai cholangiocarcinoma patients and SV40-transformed
human cholangiocyte H69 cells released exosomes into the extracellular
media. These exosomes share similar biophysical and biochemical
properties such as shape, size and speciﬁc membrane protein con-
tent of exosomes from other sources [23]. Our study provides in-
sights into the role of CCA-derived exosomes in cancer progression.
We showed that exosomes released by CCA cells in vitro have a
potential to modulate normal cholangiocyte cell motility. Thus,
exosomes released from KKU-M213 were internalized by H69 cells,
deliver functional biochemical constituents and induced cell migra-
tion and invasion, but not proliferation. By means of proteomic ap-
proach, proteins identiﬁed in H69 exosomes are mostly associated
with normal cellular activity. In contrast, exosomes from KKU-M213
cells are packed with a set of proteins having signiﬁcant potential to
intervene in cancer progression. Further, our data demonstrate that
CCA-derived exosomes carried cancer-speciﬁc proteins, highlighting a
novel source of diagnostic biomarkers and therapeutic target for
cholangiocarcinoma.
AFig. 6. KKU-M213 exosomes reduce E-cadherin and induce β-catenin expression in H69 cells. (A) Fluorescence microscopic analysis of E-cadherin and β-catenin. After treatment of H69
cellswith PBS or 200 μg/ml exosomes for 24 h, cellswereﬁxed and stained for E-cadherin andβ-catenin using anti-E-cadherin (green) and anti-β-catenin antibody (red). DAPIwas used as
a nuclear marker (blue). Samples were visualized with a confocal laser microscope. (B) Western blot analysis of β-catenin in H69 after treatment with exosomes. H69 cells were treated
with PBS or 200 μg/ml exosomes isolated from different cell lines for 24 h. Cells were then lysed and 25 μg proteinswere separated by 10% SDS-PAGE and immunoblottedwith respective
antibodies. (C) Bar graphs representing the quantitative analysis ofWestern blotting ofβ-catenin from 3 independent experiments. Data aremeans± S.E.M., *p b 0.0001 compared to PBS
control (ANOVA).
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derstanding of the molecular composition and functions of exosomes.
The concept suggests that digging out the composition and the abun-
dance of each protein in exosomes from different sources may be useful
for the identiﬁcation of novel biomarker candidates, if the proteomic pro-
ﬁling is planned in a comparative approach [24]. The subset of proteins
packed into exosomes can be functional in new environment after
being transferred to other cells, which is an exhilarating new develop-
ment to untie exosome saga. It has been reported that exosomes released
by different cell types are different with regard to their speciﬁc cellular
components [25]. Our proteomic study revealed different proteins in
two sets of exosomes (Table 1). Exploring these protein proﬁles
revealed that exosomes fromH69 andKKU-M213 cells contained sever-
al proteins which are consistent with exosome biosynthesis such as
transitional endoplasmic reticulum ATPase, molecular motors such as
tumor susceptibility gene 101 and ubiquitin. Through our proteomicapproach, we have identiﬁed exosomal proteins that are known to be
associatedwith cancer cell adhesion,migration, and invasion. A number
of these proteins have previously been identiﬁed by other researchers
in similar studies. The categorization revealed some interesting facts
that KKU-M213 exosomes contain broad spectrum of functional pro-
teins involved in cancer progression more than H69 exosomes. We
detected integrin α and β, lactadherin, and vitronectin in KKU-M213
exosomes. Recent studies demonstrated that integrins involved in
cell growth and migration through interaction with vitronectin
[26], and exogenous lactadherin directly activated AKT-dependent
pathway through interaction with integrins that subsequently lead
to neo-vascularization, supporting their functional roles in cancer
progression.
Although the functions of exosomal proteins and lipid are well char-
acterized, data concerning glycoprotein composition are scarce [27]. In
our proteomic study, we found that the exosomes from KKU-M213
1998 S. Dutta et al. / Biochimica et Biophysica Acta 1852 (2015) 1989–1999cells were enriched with a sialoglycoprotein which was identiﬁed
by peptide mass ﬁngerprinting as the galectin-3-binding protein
(LGALS3BP or LG3BP). Several lines of evidence indicate the essential
contribution of galectin-binding glycoproteins in different events asso-
ciated with tumor growth and metastasis [28]. The role of LGALS3BP in
neoplastic progression is strongly supported by numerous studies. The
expression levels of this protein in sera and neoplastic tissue from
cancer patients tightly correlate with poor prognosis and the occur-
rence of metastasis [29]. In addition, Escrevente et al. speculated that
exosomal proteins may involve in exosome/target cell interactions
and the LG3ALSBP protein may serve as an exosome biomarker for
ovarian carcinoma [27]. Since LGALS3BP is known to bind several
proteins on the cell surface such as collagens, ﬁbronectin, galectin-3
and integrin beta1, it is possible that exosomal LGALS3BP interacts
with target cells through binding with extracellular matrix proteins,
which, in turn, triggers the cellular signaling pathways associated
with cancer progression. In agreement with this notion, Kim et al. dem-
onstrated that suppression of LGALS3BP decreased cell motility com-
pared to the parental cells whereas high levels of LGALS3BP led to
increased cell migration [30].
Our MS analysis also identiﬁed several other proteins in KKU-M213
exosomes that have been established to play critical roles in cancer
progression. Up-regulations of LAT1 and 4F2hc that fasten formation
of solid tumors were detected in several cancer cell lines including
CCA cells [31,32]. Tumor associated calcium signal transducer 2 protein
stimulated several human cancer growth and up-regulation of this pro-
tein was associated with poor prognosis particularly in invasive cancers
[33]. High levels of vault protein expression are correlated with a poor
prognosis in certain cancers with some multi-drug resistant (MDR)
cancer cell lines [34]. Silencing a novel endoplasmic reticulum protein
KIAA1199 discovered earlier to induce cellmigration in invasive cancers
caused a reduction of 75% in cell migration and 80% in cell invasion [35].
Another KKU-M213 exosome protein, CD147, was reported to play im-
portant roles in hepatocellular carcinoma invasion and metastasis [36].
Epithelial cell adhesion molecule observed in KKU-M213 exosome, is a
transmembrane glycoprotein that has oncogenic potential due to its
ability to aid cell migration, invasion, and metastasis [37]. An aberrant
over-expression of pyruvate kinase isozymes M1/M2 (KPYM) associat-
edwith aggressive tumor features has been proposed to serve as a novel
biomarker and a potential treatment target for thyroid cancer [38].
Although, KKU-100 and KKU-M213 cell lines were derived from CCA
patients, however only exosomes from KKU-M213 cells induced H69
cell invasion and migration. These results might be due to the differ-
ences in their malignancy characteristics. Consistent with our ﬁnding,
KKU-M213 cells have previously been reported to exhibit higher motil-
ity and invasive abilities compared to KKU-100 cells [39]. Roles of
exosomes in cancer cell motility, metastasis and growth have recently
received wide attention. For example, Luga et al., have recently pro-
posed that ﬁbroblast exosomes promoted breast cancer cell protrusive
activity, motility and metastasis but not tumor growth through induc-
tion of autocrine Wnt-PCP signaling mechanism [40]. Although, some
of similar cancer related molecules were also present in our proteomic
study, however, Wnt signaling and PCP molecules were not detected.
Therefore, at present, the roles of these exosomal proteins in CCA carci-
nogenesis remain unclear and required further investigation. It is now
well established that accumulation of β-catenin is frequently observed
in many invasive cancers. In addition, Hayashida et al. postulated that
a loss of E-cadherin liberates β-catenin protein from the cadherin/
catenin complexes that elicits an alternative β-catenin-mediated path-
way to make cancer cells more motile and invasive [41]. Consistent
with this fact, we observed an acute loss of E-cadherin expression in
H69 cells upon treatment with KKU-M213 exosomes. Furthermore, an
increase in β-catenin expression was observed in the same treatment
indicating that KKU-M213 exosome somehow negatively inﬂuenced
the cadherin/catenin complex and subsequently facilitated an increase
in H69 cell motility.5. Conclusion
In conclusion, our results suggest that the exosomes fromKKU-M213,
an aggressive CCA cell line, might induce human cholangiocyte cell mi-
gration and invasion by a direct cell-to-cell transfer of oncogenic proteins
that inﬂuence speciﬁc intracellular mechanisms related to CCA carcino-
genesis. The exosomal oncogenic proteins may serve as diagnostic/
prognostic and therapeutic marker candidates which will have more
immediate medical applications for CCA treatment.
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